APOA1 and atherosclerosis: The first human recombinant rHDL, apoA-1M ETC-216, apoA-1M, and MDCO-216 trials were discontinued because of adverse events and lack of efficacy in inducing regression of atherosclerosis when administered on top of statin therapy, respectively [78,79].